This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Boehringer Ingelheim GmbH
Drug Names(s): Micatrio Combination Tablets, telmisartan/amlodipine besylate/hydrochlorothiazide
Micatrio is a triple combination drug consisting of AT1 receptor blocker [ARB] telmisartan, long-acting calcium channel blocker (CCB) amlodipine besylate and the thiazide diuretic hydrochlorothiazide (HCTZ).
Micatrio Combination Tablets constitute the Micardis family along with Micardis 20mg/40mg/80mg Tablets, Micombi Combination Tablets AP/BP, a combination drug with HCTZ and Micamlo Combination Tablets AP/BP, a combination drug with the long-acting CCB amlodipine besylate.
Full details of the deal history for the Micardis family can be viewed under Micardis.
Astellas and Boehringer
In January 2002, Boehringer Ingelheim and Yamanouchi Pharmaceutical Co. signed a Letter of Intent on the co-promotion of telmisartan in Japan. Following approval in Japan, telmisartan, which will be manufactured by Nippon Boehringer Ingelheim, is going to be jointly marketed by both companies and distributed by Yamanouchi.
In April 2005, Fujisawa and Yamanouchi officially merged to form Astellas Pharma.
In May 2010, Nippon Boehringer Ingelheim and Astellas Pharma announced that they have concluded new contracts on sales and co-promotion for telmisartan (Micardis family). The term of current contracts will end in December 2012, but pursuant to new contracts, the partnership will continue through December 2016.
In January 2016, Boehringer Ingelheim and Astellas have extended the agreement...See full deal structure in Biomedtracker
Partners: Astellas Pharma, Inc.
Additional information available to subscribers only: